Investigation of the mechanisms underlying the resistance phenotype revealed enhanced activation of Chk1 and Chk2 kinases in the CD113+ glioma cells compared to CD133− cells, while no increase in DNA repair pathways was observed. This evidence concerns the gene PROM1 and central nervous system cancer.